Aggressive prolactinoma treated with a large dose of dopamine agonist and radiotherapy

Introduction: Prolactinomas account for approximately 40% of all pituitary adenomas, with an estimated prevalence of 100 prolactinomas per million adults. Dopamine agonists currently represent the mainstay of treatment. Nevertheless, increasing dopamine-agonist dosage, surgery, and radiotherapy may be necessary in some cases, such as aggressive, dopamine-agonist resistant or atypical prolactinomas.